In the continued search for an improvement on the current standard care for Glioblastoma, a new treatment has been utilised by neuro-oncologist Andrew B. Lassman and his research team at Columbia University, in the United States.
What is the treatment?
The oral medication ‘Selinexor’ was used in this clinical trial with the aim to improve the outcome, survivability and quality of life for the patients living with GBM.
The drug works by helping to export certain proteins from the tumour site, therefore allowing the body to retain other proteins that benefit the patient by supressing the tumour and inducing other tumour suppressor functions.
What were the results?
In 28% of Glioblastoma patients that had the drug during the clinical trial, there was an observed reduction in tumour size. Additionally, this trial helped to determine the appropriate dosage of Selinexor for future trials that will be safe and effective for the community.
Some side effects were noted with the most common being fatigue, closely followed by nausea. Over half of the individuals on this study suffered these unfortunate side effects, but they were said to be manageable with support from specialists along with appropriate adjustments to their dosage.
It was determined that are reasonable grounds to continue to study the effectiveness of this drug in the future. For more scientific information, find the study here.
If you would like to use your experience and insight to support clinical research, consider signing up to be a PRIME advocate for brainstrust.
If you or someone you love is living with a brain tumour and have any questions around this latest news, or want to access support, give us a call on 01983 292 405 or email firstname.lastname@example.org. You can also visit our little brainstrust website which features support for children affected by brain tumour.